Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimlovisertib (PF-06650833) DDI with Oral Contraceptives
NCT05064332Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zimlovisertib in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration for Ethinyl Estradiol, Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration for Levonorgestrel and 2 more. Started Oct 2021; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05064332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064332.